From “doing digital” to “being digital,” that’s where the life sciences and health care industry needs to go. To help your business navigate digital disruption, this series provides a life sciences and health care perspective on Deloitte’s 2018 Tech Trends report. From blockchain to digital reality to the no-collar workforce, explore eight trends that are shaping strategic and operational transformations and redefining life sciences and health care.
The Maryland Tech Council (MTC) concluded its Bio+Tech18 Conference yesterday in Baltimore with the announcement of Remedy Plan Therapeutics as the winner of its Inaugural Start-Up Pitch Contest. Remedy Plan Therapeutics is a biotechnology company developing drugs that target cancer stem cells to inhibit tumor growth and proliferation.
Put a Regulatory consultant, a lawyer, and a venture capitalist in a room together and what do you get? Come to the National Capital Chapter SoPE event on October 17th, 2018 to find out!
Dr. Bill Hearl is the Founder and Chief Executive Officer of Immunomic Therapeutics, Inc. (“ITI”). He is an experienced and successful scientific businessman and bio-entrepreneur, having founded both ITI and formerly Capital Genomix in 2000. Dr. Hearl has moved ITI steadily forward from an initial license agreement with the Geron Corporation in 2006 to an animal health license in 2012 and then most recently to two license deals with Astellas Pharma for the treatment of allergies, one for Japanese red cedar and a second global allergy license. The second deal brought ITI an upfront payment of $300,000,000 and established the Company as one of the leading entities in nucleic acid research. Dr. Hearl funded the Company by following a strategy of seeking a series of angel investment rounds which raised in aggregate over $12 million to drive the development of its allergy products. Prior to founding ITI and Capital Genomix, he was a senior executive at Kirkegaard & Perry Labs and then held various R&D positions at Life Technologies and Pharmacia. Dr. Hearl holds a Ph.D. in Biochemistry from the University of Tennessee (Oak Ridge & Knoxville) and holds multiple patents in the field of gene immunization.
Listen now on iTunes , Google Play , and TuneIn.
The Biden Cancer Summit takes place Friday, September 21st in Washingtin, D. C. The event aims to promote new solutions, bring together problem solvers, and tell stories that epitomize what it means to be cancer FIERCE. The Summit is the flagship event of more than 450 Biden Cancer Community Summits convening throughout September 21st, all focused on improving the cancer journey for patients, their families, and caregivers.
Good morning and thank you for having me here today.
One of the most critical points on a patient’s journey is the moment of diagnosis. The moment when you find out what’s wrong. What the options are. The uncertainty of the unknown can be the hardest part of a grave diagnosis. And the emotional health that comes with more confidence and more certainty is inextricably linked to physical health and outcomes.
The National Disease Research Interchange (NDRI) has been awarded more than $800,000 by the National Institutes of Health (NIH) to supplement a current $6.5 million grant provided to NDRI that supports continued national leadership with the recovery and distribution of human organs and tissues for medical research over the course of five years. The supplemental awards provide support for NDRI to serve as a human biospecimen resource for research focused specifically on Alzheimer’s disease, Autism Spectrum Disorder (ASD) and HIV/AIDS. The three awards are supplements to NDRI’s Human Tissues and Organs for Research Resources (HTORR) program which has been supported by the NIH since 1987.
The second minibus package includes the fiscal year 2019 Labor, Health and Human Services, and Education (LHHS) funding bill, which includes funding for programs within the Departments of Labor, Health and Human Services, and Education, and other related agencies, including the Social Security Administration.
Even under the no-holds-barred rules of biotech, it’s a particularly shrewd move, one that might prompt guffaws from knowing insiders.
An artificial intelligence start-up founded by three insiders at Memorial Sloan Kettering Cancer Center debuted with great fanfare in February, with $25 million in venture capital and the promise that it might one day transform how cancer is diagnosed.
